Navigation Links
InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
Date:3/2/2010

king Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, which reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated regulatory timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy analyses and safety results the company has submitted in support of its NDA and MAA filings. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail in the risk factors attached as Exhibit 99.3 to InterMune's Form 8-K filed with the SEC on January 20, 2010, and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulator
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Guggenheim Securities, the investment banking and capital ... of veteran equity analyst Charles "Tony" Butler as a ... focus on the biotech/biopharma sector. " Tony ... and a broad network of relationships in his industry," ... Head of Equities at Guggenheim Securities. "His insights will ...
(Date:8/27/2014)... Research and Markets has announced ... & Paper Industry Report 2014" report to their ... & Paper Industry Report 2014 is a professional and ... enzyme for pulp & paper industry. The ... definitions, classifications, applications and industry chain structure. The enzyme ...
(Date:8/27/2014)... 27, 2014 Tris Pharma, a specialty pharmaceutical ... announced that it has been selected as an award ... 2014 Awards for Excellence competition in the ... panel of judges from SCORE (Counselors to America,s Small ... be honored at a gala event to be held ...
(Date:8/27/2014)... After the boom of the energy drink ... craze is going to be the stress relief drinks. ... Stress Relief energy pattern which can be applied to ... beverage, including minerals, herbs and liquids. Stress Relief generates ... into rapid recovery and helping to adapt more quickly. ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Enzyme for Pulp & Paper Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
... Calif., June 5 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical,Inc. (Nasdaq ... its third,enzyme replacement therapy (ERT) for the treatment ... BioMarin plans to initiate a Phase,1/2 clinical trial ... two MPS drugs on the market, we plan ...
... ) notes that FDA has published a notice of a ... to,be held on July 23, 2008. The Committee will address ... " ... presentations from the Office of Generic Drugs (OGD) ... treat gastrointestinal (GI) conditions ... " For over ...
... Will be Presented at the American Society for Mass ... 56th ASMS Conference in Denver, June ... Inc.,(Nasdaq: BNVI ) today announced that it has ... platform that allows for the rapid, specific, sensitive,automated quantification ...
Cached Biology Technology:BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome 2BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome 3BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome 4Viropharma Comments On Upcoming FDA Advisory Committee Meeting 2Viropharma Comments On Upcoming FDA Advisory Committee Meeting 3Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds 2Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds 3
(Date:8/27/2014)... may not be getting effective doses of the HIV ... The initial dosing studies, completed before the drug was ... a protein that is key to removing maraviroc from ... maximum levels of the protein including nearly half ... their bodies compared to those who lack the protein ...
(Date:8/27/2014)... found in forests has created a thriving habitat for ... new University of Georgia study has found. , Japanese ... the early 1900s, is one of the most pervasive ... dozen states in the past century, particularly in the ... can survive in widely diverse ecosystems and has been ...
(Date:8/27/2014)... entering what is described by the Volunteer Wildfire Services ... Eastern Cape provincial government warned residents in certain parts ... and veld fires. A high veld fire danger ... the coast in the Great Kei and Mnquma area. ... during thunderstorms. The thunderstorms bring lightning strikes and ...
Breaking Biology News(10 mins):Dosage of HIV drug may be ineffective for half of African-Americans 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3
... reporting dramatic new real-world evidence supporting the idea that ... It appears in a new study showing a connection ... stored drinking water, and health in households in a ... Environmental Science & Technology , a semi-monthly journal. ...
... , Menlo Park, Calif. The U.S. Department of ... of the Linac Coherent Light Source (LCLS), the world,s ... laser at the laboratory. The LCLS, which began operation ... laser light which are already providing new insights into ...
... project of the European Union has, in addition to the ... of stakeholders interested in making healthier cereal foods as part ... continue the activities and work of the HEALTHGRAIN project which ... Sweden. The HEALTHGRAIN Forum will be the future platform ...
Cached Biology News:First X-ray laser's early success brings approval for next-phase facility 2The HEALTHGRAIN Forum will work for cereal foods and health 2
Multidrop Micro high speed 1 l bulk reagent dispenser rapidly, precisely and accurately dispenses microvolumes of 1-50 l into 384- and 96-well microplates....
...
...
Buckets for tube holder inserts...
Biology Products: